CareMessage, the largest patient activation platform in the United States for underserved populations, today announced the launch of their AI Assistant, adding ethical AI tools to their market-leading ...
Stephen Abreu has been appointed by the Board as Executive Director. He will lead the organization's overall strategy and ...
In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...
The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...
The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...
Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback